Login / Signup

Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes.

Jeremy BigotAna I LalanneFrancesca LucibelloPaul GueguenAlexandre HouyStephane DayotOlivier GanierJules GiletJimena ToselloFariba NematiGaëlle PierronJoshua J WaterfallRaymond L BarnhillSophie GardratSophie Piperno-NeumannTatiana PopovaVanessa MassonDamarys LoewPascale MarianiNathalie CassouxSebastian AmigorenaManuel J RodriguesSamar AlsafadiMarc-Henri SternOlivier Lantz
Published in: Cancer discovery (2021)
Disruption of splicing patterns due to mutations of genes coding splicing factors in tumors represents a potential source of tumor neoantigens, which would be both public (shared between patients) and tumor-specific (not expressed in normal tissues). In this study, we show that mutations of the splicing factor SF3B1 in uveal melanoma generate such immunogenic neoantigens. Memory CD8+ T cells specific for these neoantigens are preferentially found in 20% of patients with uveal melanoma bearing SF3B1-mutated tumors. Single-cell analyses of neoepitope-specific T cells from the blood identified large clonal T-cell expansions, with distinct effector transcription patterns. Some of these expanded T-cell receptors are also present in the corresponding tumors. CD8+ T-cell clones specific for the neoepitopes specifically recognize and kill SF3B1-mutated tumor cells, supporting the use of this new family of neoantigens as therapeutic targets. SIGNIFICANCE: Mutations of the splicing factor SF3B1 in uveal melanoma generate shared neoantigens that are uniquely expressed by tumor cells, leading to recognition and killing by specific CD8 T cells. Mutations in splicing factors can be sources of new therapeutic strategies applicable to diverse tumors.This article is highlighted in the In This Issue feature, p. 1861.
Keyphrases